Hence, this study attempted to address this problem by analyzing the mRNA expression and mutations of different MAPs via microarray technology (19) and to identify the therapeutic potential personalized targets and prognostic value of MAPs for NSCLC patients. The gene discussed is C3orf62; the disease is non-small cell lung carcinoma.